Instrument Inactif

Communiqués Rafarma Pharmaceuticals, Inc. Other OTC

Actions

RAFA

US75062C1009

Communiqués

12/03/25	Rafarma Pharmaceuticals to Present at the Virtual Life Science Investor Forum March 13th	AQ
18/12/24	Rafarma pharmaceutical updates	AQ
04/07/24	Rafarma pharmaceutical updates: registration of Rafarma microspheres in South Korea	AQ
03/07/24	Rafarma pharmaceutical updates: creation of a joint research and production enterprise in Busan (South Korea) between Rafarma and the Korean pharmaceutical company Woods Medical Care	AQ
11/12/23	Rafarma pharmaceutical updates: agreements with Shri Lanka pharmaceutical company Kelun Lifesciences (Pvt) Ltd and El Salvador University	AQ
30/11/23	Rafarma Pharmaceutical news update	AQ
15/08/22	Rafarma Pharmaceuticals : RAFA Financials Q2	PU
29/04/22	Rafarma Pharmaceuticals strengthens its position in Central Asia	AQ
07/02/22	Rafarma’s Slavich Noya Technology Division Expands Printing Production	AQ
21/12/21	RAFA Enters into Negotiations with JINR for Ultra-Cutting Edge Nuclear Research	AQ
17/12/21	RAFA To Add Major Component to the Tashkent Pharma Park	AQ
19/11/21	Explosive Growth Launches Kraspharma Into REMEDIUM TOP-5	AQ
19/08/21	Rafarma Enters Negotiations With Leading Global Producer of Precious Metals to Localize Production of Platinum-Based Cancer Drugs	GL
10/08/21	Letter to Shareholders from the Chairman of the Board Ilya Shpurov	GL
30/07/21	Rafarma Signs Trilateral Investment Agreement Officially Launching Tashkent Pharmaceutical Plant Build	GL
18/05/21	Rafarma’s Global Pharmaceutical Strategy At A Glance	GL
07/05/21	Rafarma To Expand Proton Therapy Centers	GL
30/04/21	Rafarma and Haifa Technopark Enter Talks for Joint Venture	GL
04/03/21	Rafarma Embarks on Aggressive Global Partnerships Plan	GL
29/01/21	Rafarma Secures Joint Venture Agreement with the Pharmaceutical Industry Development Agency of Uzbekistan	GL
09/12/20	Rafarma Merger Company Bebig Approved For Production And Sale Of Yttrium-90 For Treatment Of Inoperable Liver Cancer	GL
01/12/20	Rafarma Inks Joint Venture Agreement with Vaccines Lab SDN BHD of Malaysia	GL
09/11/20	Rafarma Pharmaceuticals : Letter To Shareholders from Chairman Ilya Shpurov	AQ
09/11/20	Letter To Shareholders from Chairman Ilya Shpurov	GL
04/11/20	Rafarma Pharmaceuticals : Auditing Firm L J Soldinger Associates Retained for Rafarma Biocogency Merger	AQ